Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 Jan;48(1):47–52. doi: 10.1136/gut.48.1.47

Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma

R Siddheshwar 1, J Gray 1, S Kelly 1
PMCID: PMC1728168  PMID: 11115822

Abstract

BACKGROUND—The relationship between plasma gastrin levels and colorectal cancer is controversial. When confounding factors which increase plasma gastrin levels are taken into account, it has been shown that gastrin levels are not elevated in patients with colorectal cancer. However, these studies only measured amidated gastrin. Total gastrin (which includes unprocessed, partially processed, and mature forms of gastrin) has been shown to be elevated in patients with colorectal cancer.
AIMS—The aim of this study was to determine whether fasting plasma levels of progastrin, amidated gastrin, or glycine extended gastrin are elevated in patients with colorectal cancer or colorectal polyps compared with controls.
METHODS—Progastrin, amidated gastrin, and glycine extended gastrin were estimated by radioimmunoassay using the following antibodies: L289, 109-21, and L2. Blood samples were analysed for Helicobacter pylori by an enzyme linked immunosorbent assay.
RESULTS—Median progastrin levels were significantly higher in the cancer group (27.5 pmol/l) than in the polyp (⩽15 pmol/l) or control (⩽15 pmol/l) group (p=0.0001). There was no difference in median levels of amidated gastrin between groups. Median levels of amidated gastrin were significantly higher in H pylori positive patients (19 pmol/l) than in H pylori negative patients (8 pmol/l) (p=0.0022). Median plasma progastrin levels were significantly higher for moderately dysplastic polyps (38 pmol/l) compared with mildly dysplastic (15 pmol/l) and severely dysplastic (15 pmol/l) polyps (p=0.05).
CONCLUSIONS—Plasma levels of progastrin, but not amidated gastrin or glycine extended gastrin, are significantly elevated in patients with colorectal cancer compared with those with colorectal polyps or controls, irrespective of their H pylori status. We conclude that measuring plasma progastrin levels in patients with colorectal cancer is warranted.


Keywords: progastrin; glycine extended gastrin; colorectal carcinoma

Full Text

The Full Text of this article is available as a PDF (149.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Plasma progastrin levels in control, cancer, and polyp groups. Median values are shown (***p=0.0001, cancers v controls and polyps).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin G. S., Shulkes A. Gastrin, gastrin receptors and colorectal carcinoma. Gut. 1998 Apr;42(4):581–584. doi: 10.1136/gut.42.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beauchamp R. D., Townsend C. M., Jr, Singh P., Glass E. J., Thompson J. C. Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice. Ann Surg. 1985 Sep;202(3):303–309. doi: 10.1097/00000658-198509000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brinton L. A., Gridley G., Hrubec Z., Hoover R., Fraumeni J. F., Jr Cancer risk following pernicious anaemia. Br J Cancer. 1989 May;59(5):810–813. doi: 10.1038/bjc.1989.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Charnley R. M., Thomas W. M., Stanley J., Morris D. L. Serum gastrin concentrations in colorectal cancer patients. Ann R Coll Surg Engl. 1992 Mar;74(2):138–141. [PMC free article] [PubMed] [Google Scholar]
  5. Ciccotosto G. D., McLeish A., Hardy K. J., Shulkes A. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology. 1995 Oct;109(4):1142–1153. doi: 10.1016/0016-5085(95)90572-3. [DOI] [PubMed] [Google Scholar]
  6. Dickinson C. J. Relationship of gastrin processing to colon cancer. Gastroenterology. 1995 Oct;109(4):1384–1388. doi: 10.1016/0016-5085(95)90603-7. [DOI] [PubMed] [Google Scholar]
  7. Fontanesi B. V., Boris B., Delcio M., Manoukian F. N. Gastrin levels in patients with colorectal cancer. Hepatogastroenterology. 1997 Jul-Aug;44(16):1082–1084. [PubMed] [Google Scholar]
  8. Graffner H., Singh G., Chaudry I., Milsom J. W. Omeprazole-induced hypergastrinemia does not influence growth of colon carcinoma. Dig Dis Sci. 1992 Apr;37(4):485–489. doi: 10.1007/BF01307567. [DOI] [PubMed] [Google Scholar]
  9. Hollande F., Imdahl A., Mantamadiotis T., Ciccotosto G. D., Shulkes A., Baldwin G. S. Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. Gastroenterology. 1997 Nov;113(5):1576–1588. doi: 10.1053/gast.1997.v113.pm9352860. [DOI] [PubMed] [Google Scholar]
  10. Hoosein N. M., Kiener P. A., Curry R. C., Rovati L. C., McGilbra D. K., Brattain M. G. Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res. 1988 Dec 15;48(24 Pt 1):7179–7183. [PubMed] [Google Scholar]
  11. Kameyama M., Fukuda I., Imaoka S., Nakamori S., Iwanaga T. Level of serum gastrin as a predictor of liver metastasis from colorectal cancer. Dis Colon Rectum. 1993 May;36(5):497–500. doi: 10.1007/BF02050017. [DOI] [PubMed] [Google Scholar]
  12. Karlin D. A., McBath M., Jones R. D., Elwyn K. E., Romsdahl M. M. Hypergastrinemia and colorectal carcinogenesis in the rat. Cancer Lett. 1985 Oct;29(1):73–78. doi: 10.1016/0304-3835(85)90125-9. [DOI] [PubMed] [Google Scholar]
  13. Kikendall J. W., Glass A. R., Sobin L. H., Bowen P. E. Serum gastrin is not higher in subjects with colonic neoplasia. Am J Gastroenterol. 1992 Oct;87(10):1394–1397. [PubMed] [Google Scholar]
  14. Kochman M. L., DelValle J., Dickinson C. J., Boland C. R. Post-translational processing of gastrin in neoplastic human colonic tissues. Biochem Biophys Res Commun. 1992 Dec 15;189(2):1165–1169. doi: 10.1016/0006-291x(92)92326-s. [DOI] [PubMed] [Google Scholar]
  15. Koh T. J., Goldenring J. R., Ito S., Mashimo H., Kopin A. S., Varro A., Dockray G. J., Wang T. C. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology. 1997 Sep;113(3):1015–1025. doi: 10.1016/s0016-5085(97)70199-9. [DOI] [PubMed] [Google Scholar]
  16. Kusyk C. J., McNiel N. O., Johnson L. R. Stimulation of growth of a colon cancer cell line by gastrin. Am J Physiol. 1986 Nov;251(5 Pt 1):G597–G601. doi: 10.1152/ajpgi.1986.251.5.G597. [DOI] [PubMed] [Google Scholar]
  17. Lamberts R., Wartenberg T., Creutzfeldt W. Role of circulating gastrin in colorectal adenomas and carcinomas. Digestion. 1999 Mar-Apr;60(2):101–109. doi: 10.1159/000007634. [DOI] [PubMed] [Google Scholar]
  18. Lüttichau H. R., Van Solinge W. W., Nielsen F. C., Rehfeld J. F. Developmental expression of the gastrin and cholecystokinin genes in rat colon. Gastroenterology. 1993 Apr;104(4):1092–1098. doi: 10.1016/0016-5085(93)90278-k. [DOI] [PubMed] [Google Scholar]
  19. Mihas A. A., Maliakkal R. J., Shueke M., Achord J. L. Serum gastrin levels in patients with colorectal cancer and adenomatous polyps: a prospective study. Res Commun Mol Pathol Pharmacol. 1995 Nov;90(2):301–304. [PubMed] [Google Scholar]
  20. Nemeth J., Taylor B., Pauwels S., Varro A., Dockray G. J. Identification of progastrin derived peptides in colorectal carcinoma extracts. Gut. 1993 Jan;34(1):90–95. doi: 10.1136/gut.34.1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Niv Y., Heizelracht N., Lamprecht S. A., Sperber A. D., Fraser G. M., Schwartz B. Gastrin levels in colorectal cancer. Isr J Med Sci. 1997 Mar;33(3):186–189. [PubMed] [Google Scholar]
  22. Orbuch M., Venzon D. J., Lubensky I. A., Weber H. C., Gibril F., Jensen R. T. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1996 Mar;41(3):604–613. doi: 10.1007/BF02282349. [DOI] [PubMed] [Google Scholar]
  23. Penman I. D., el-Omar E., Ardill J. E., McGregor J. R., Galloway D. J., O'Dwyer P. J., McColl K. E. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology. 1994 May;106(5):1263–1270. doi: 10.1016/0016-5085(94)90018-3. [DOI] [PubMed] [Google Scholar]
  24. Renga M., Brandi G., Paganelli G. M., Calabrese C., Papa S., Tosti A., Tomassetti P., Miglioli M., Biasco G. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut. 1997 Sep;41(3):330–332. doi: 10.1136/gut.41.3.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Romani R., Howes L. G., Morris D. L. Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro. Aust N Z J Surg. 1996 Apr;66(4):235–237. doi: 10.1111/j.1445-2197.1996.tb01173.x. [DOI] [PubMed] [Google Scholar]
  26. Seitz J. F., Giovannini M., Gouvernet J., Gauthier A. P. Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol. 1991 Oct;13(5):541–545. doi: 10.1097/00004836-199110000-00013. [DOI] [PubMed] [Google Scholar]
  27. Seva C., Dickinson C. J., Yamada T. Growth-promoting effects of glycine-extended progastrin. Science. 1994 Jul 15;265(5170):410–412. doi: 10.1126/science.8023165. [DOI] [PubMed] [Google Scholar]
  28. Smith J. P., Wood J. G., Solomon T. E. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci. 1989 Feb;34(2):171–174. doi: 10.1007/BF01536047. [DOI] [PubMed] [Google Scholar]
  29. Sobhani I., Lehy T., Laurent-Puig P., Cadiot G., Ruszniewski P., Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology. 1993 Jul;105(1):22–30. doi: 10.1016/0016-5085(93)90006-x. [DOI] [PubMed] [Google Scholar]
  30. Suzuki H., Matsumoto K., Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum. 1988 Sep;31(9):716–717. doi: 10.1007/BF02552592. [DOI] [PubMed] [Google Scholar]
  31. Talley N. J., Chute C. G., Larson D. E., Epstein R., Lydick E. G., Melton L. J., 3rd Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med. 1989 Nov 1;111(9):738–742. doi: 10.7326/0003-4819-111-9-738. [DOI] [PubMed] [Google Scholar]
  32. Thorburn C. M., Friedman G. D., Dickinson C. J., Vogelman J. H., Orentreich N., Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology. 1998 Aug;115(2):275–280. doi: 10.1016/s0016-5085(98)70193-3. [DOI] [PubMed] [Google Scholar]
  33. Upp J. R., Jr, Singh P., Townsend C. M., Jr, Thompson J. C. Clinical significance of gastrin receptors in human colon cancers. Cancer Res. 1989 Jan 15;49(2):488–492. [PubMed] [Google Scholar]
  34. Van Solinge W. W., Nielsen F. C., Friis-Hansen L., Falkmer U. G., Rehfeld J. F. Expression but incomplete maturation of progastrin in colorectal carcinomas. Gastroenterology. 1993 Apr;104(4):1099–1107. doi: 10.1016/0016-5085(93)90279-l. [DOI] [PubMed] [Google Scholar]
  35. Vanderstraeten E. F., De Vos M. M., Versieck J. M., Elewaut A. P. Serum gastrin levels and colorectal neoplasia. Dis Colon Rectum. 1995 Feb;38(2):172–176. doi: 10.1007/BF02052446. [DOI] [PubMed] [Google Scholar]
  36. Varis K., Ihamäki T., Härkönen M., Samloff I. M., Siurala M. Gastric morphology, function, and immunology in first-degree relatives of probands with pernicious anemia and controls. Scand J Gastroenterol. 1979;14(2):129–139. doi: 10.3109/00365527909179858. [DOI] [PubMed] [Google Scholar]
  37. Varro A., Dockray G. J., Bate G. W., Vaillant C., Higham A., Armitage E., Thompson D. G. Gastrin biosynthesis in the antrum of patients with pernicious anemia. Gastroenterology. 1997 Mar;112(3):733–741. doi: 10.1053/gast.1997.v112.pm9041234. [DOI] [PubMed] [Google Scholar]
  38. Wang T. C., Koh T. J., Varro A., Cahill R. J., Dangler C. A., Fox J. G., Dockray G. J. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest. 1996 Oct 15;98(8):1918–1929. doi: 10.1172/JCI118993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Watson S. A., Clifford T., Sykes R. E., Robinson E., Steele R. J. Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism. Eur J Cancer. 1995 Nov;31A(12):2086–2092. doi: 10.1016/0959-8049(95)00451-3. [DOI] [PubMed] [Google Scholar]
  40. Watson S. A., Durrant L. G., Crosbie J. D., Morris D. L. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer. 1989 Apr 15;43(4):692–696. doi: 10.1002/ijc.2910430425. [DOI] [PubMed] [Google Scholar]
  41. Watson S. A., Michaeli D., Grimes S., Morris T. M., Robinson G., Varro A., Justin T. A., Hardcastle J. D. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 1996 Feb 15;56(4):880–885. [PubMed] [Google Scholar]
  42. Winsett O. E., Townsend C. M., Jr, Glass E. J., Thompson J. C. Gastrin stimulates growth of colon cancer. Surgery. 1986 Mar;99(3):302–307. [PubMed] [Google Scholar]
  43. Wong K., Beardshall K., Waters C. M., Calam J., Poston G. J. Postprandial hypergastrinaemia in patients with colorectal cancer. Gut. 1991 Nov;32(11):1352–1354. doi: 10.1136/gut.32.11.1352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Yapp R., Modlin I. M., Kumar R. R., Binder H. J., Dubrow R. Gastrin and colorectal cancer. Evidence against an association. Dig Dis Sci. 1992 Apr;37(4):481–484. doi: 10.1007/BF01307566. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES